Ionis Pharmaceuticals (IONS) Stock Insights

IONS price $44.90 +0.94 +2.14%

Ticker
IONS
Price
$44.90
Change
+0.94 +2.14%
Market cap ?
$7.46B
P/E ?
-12.55
Forward P/E ?
112.06
Dividend yield ?
0.00%
Beta ?
0.38
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
49
Value
60
Quality
33
Growth
53

Stocklytics score rationale: value 60, quality 33, growth 53.

Financials

2016201720182019202020212022202320242025
3727760005141790005996740001122599000729264000810456000587367000787647000705138000944000000

Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy…

Fair value

IONS fair value $13.01. Price $44.90. Price is 245% above fair value.

Above fair value, and more expensive than usual. A larger premium than on 61% of days in the past 5 years.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 260.21M. Growth 0.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 8.70% (beta 0.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 166.18M. Net debt 2.24B. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Model uncertainty high for this stock

Compare IONS

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-04—-1.22—181.56M
2026-07-29-0.69-1.09268.00M189.10M
2026-04-29-0.56-0.85246.00M195.56M
2026-02-25-1.41-1.24203.00M156.07M
2025-10-29-0.61-1.15156.72M153.57M
2025-07-300.860.27452.05M131.75M
2025-04-30-0.75-1.11131.61M150.59M
2025-02-19-0.66-1.09226.58M131.14M
2024-11-06-0.95-1.16133.81M144.44M
2024-08-01-0.45-0.92225.25M150.07M
2024-05-07-0.98-1.05119.00M131.42M
2024-02-21-0.06-0.83324.50M174.76M
2023-11-02-1.03-1.04144.21M132.90M
2023-08-09-0.60-0.90188.41M138.83M
2023-05-03-0.87-0.91130.52M140.51M
2023-02-22-0.37-1.06151.89M160.13M
2022-11-09-0.33-0.74159.77M143.95M
2022-08-09-0.74-0.62133.79M140.54M
2022-05-04-0.46-0.71141.92M122.46M
2022-02-241.410.28440.01M275.55M
2021-11-03-0.58-0.53133.09M163.67M
2021-08-04-0.57-0.60125.75M126.00M
2021-05-05-0.64-0.53111.61M138.50M
2021-02-24-2.440.24290.28M274.45M
2020-11-04-0.22-0.09160.08M65.49M
2020-08-05-0.23-0.28145.54M177.18M
2020-05-06-0.10-0.11133.37M45.73M
2020-02-261.410.93493.68M358.69M
2019-11-060.18-0.32167.89M298.47M
2019-08-07-0.01-0.27163.81M4.42B
2019-05-090.920.43297.21M282.83M
2019-02-272.420.40192.12M4.35M
2018-11-06-0.03-0.16145.40M775.44M
2018-08-07-0.05-0.02117.75M36.54M
2018-05-04-0.01-0.01144.42M433.26M
2018-02-270.02-0.08172.30M86.15M
2017-11-07-0.02-0.05118.31M200.56M
2017-08-08-0.09-0.04112.27M96.67M
2017-05-090.03-0.10115.80M183.84M
2017-02-280.24-0.12160.35M91.63M

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-10-16Devers Shannon L.Sell1.36K$43.5459.08K
2026-10-16Swayze EricSell53$43.542.31K
2026-10-15Devers Shannon L.Sell2.82K——
2026-10-15Devers Shannon L.Buy2.82K——
2026-10-15Swayze EricSell125——
2026-10-15Swayze EricBuy125——
2026-08-31BENNETT C FRANKBuy110$51.315.64K
2026-08-31O'NEIL PATRICK R.Buy63$51.313.23K
2026-08-31Monia Brett PBuy98$51.315.03K
2026-08-31Birchler BrianBuy58$51.312.98K
2026-07-31Hayden Michael RBuy5.00K$51.60258.00K
2026-07-30Hayden Michael RBuy15.00K$53.38800.70K
2026-07-15Reikes Peter NBuy3.40K——
2026-07-15HANTSON LUDWIGBuy3.40K——
2026-07-15HERMAN JOAN EBuy5.22K——
2026-07-15HERMAN JOAN ESell5.22K——
2026-07-15BERTHELSEN SPENCER RBuy5.22K——
2026-07-15BERTHELSEN SPENCER RSell5.22K——
2026-07-07BENNETT C FRANKSell5.54K$83.58462.69K
2026-07-07BENNETT C FRANKBuy15.00K$85.461.28M
2026-07-07BENNETT C FRANKSell15.00K$85.461.28M
2026-07-07BENNETT C FRANKSell15.00K$85.461.28M
2026-07-07Diaz Allene M.Buy10.11K$47.11476.33K
2026-07-07Diaz Allene M.Sell10.11K$85.42863.64K
2026-07-07Diaz Allene M.Sell10.11K$47.11476.33K
2026-07-07Kordasiewicz Holly B.Sell362$84.3030.52K
2026-07-01YANG MICHAEL J.Buy2.30K——
2026-07-01YANG MICHAEL J.Buy5.37K$79.19425.17K
2026-07-01LOSCALZO JOSEPHBuy2.30K——
2026-07-01LOSCALZO JOSEPHBuy5.37K$79.19425.17K
2026-07-01HERMAN JOAN EBuy2.30K——
2026-07-01HERMAN JOAN EBuy5.37K$79.19425.17K
2026-07-01KLEIN JOSEPH IIIBuy11.52K$39.94460.03K
2026-07-01KLEIN JOSEPH IIISell99$79.457.87K
2026-07-01KLEIN JOSEPH IIIBuy2.30K——
2026-07-01KLEIN JOSEPH IIISell11.42K$79.04902.55K
2026-07-01KLEIN JOSEPH IIIBuy5.37K$79.19425.17K
2026-07-01KLEIN JOSEPH IIISell11.52K$39.94460.03K
2026-07-01Hayden Michael RBuy2.30K——
2026-07-01Hayden Michael RBuy5.37K$79.19425.17K
2026-07-01Diaz Allene M.Buy2.30K——
2026-07-01Diaz Allene M.Buy5.37K$79.19425.17K
2026-07-01BERTHELSEN SPENCER RBuy2.30K——
2026-07-01BERTHELSEN SPENCER RBuy5.37K$79.19425.17K
2026-06-26Baroldi JosephBuy1.77K$32.6057.67K
2026-06-26Baroldi JosephBuy3.87K$56.78219.51K
2026-06-26Baroldi JosephSell5.63K$80.16451.70K
2026-06-26Baroldi JosephSell3.87K$56.78219.51K
2026-06-26Baroldi JosephSell1.77K$32.6057.67K
2026-06-26O'NEIL PATRICK R.Sell3.07K$80.00245.52K
2026-06-26Schneider EugeneBuy26.00K$60.891.58M
2026-06-26Schneider EugeneSell26.00K$81.052.11M
2026-06-26Schneider EugeneSell26.00K$60.891.58M
2026-06-26Monia Brett PBuy50.00K$56.782.84M
2026-06-26Monia Brett PSell50.00K$80.594.03M
2026-06-26Monia Brett PSell50.00K$56.782.84M
2026-06-25Monia Brett PBuy21.07K$32.60686.95K
2026-06-25Monia Brett PSell21.07K$78.491.65M
2026-06-25Monia Brett PSell21.07K$32.60686.95K
2026-06-25Swayze EricSell10.60K$79.18839.49K
2026-06-24Monia Brett PBuy14.56K$32.60474.82K
2026-06-24Monia Brett PSell14.56K$78.411.14M
2026-06-24Monia Brett PSell14.56K$32.60474.82K
2026-06-15BERTHELSEN SPENCER RBuy8.00K$24.42195.36K
2026-06-15BERTHELSEN SPENCER RSell8.00K$73.49587.92K
2026-06-15BERTHELSEN SPENCER RSell8.00K$24.42195.36K
2026-06-12Kordasiewicz Holly B.Buy19.89K$56.781.13M
2026-06-12Kordasiewicz Holly B.Buy12.00K$32.60391.20K
2026-06-12Kordasiewicz Holly B.Buy21.00K$60.891.28M
2026-06-12Kordasiewicz Holly B.Sell41.00K$73.093.00M
2026-06-12Kordasiewicz Holly B.Buy7.95K$60.89484.14K
2026-06-12Kordasiewicz Holly B.Sell19.84K$74.051.47M
2026-06-12Kordasiewicz Holly B.Sell7.95K$60.89484.14K
2026-06-12Kordasiewicz Holly B.Sell12.00K$32.60391.20K
2026-06-12Kordasiewicz Holly B.Sell19.89K$56.781.13M
2026-06-12Kordasiewicz Holly B.Sell21.00K$60.891.28M
2026-06-04Reikes Peter NBuy10.75K$75.13807.87K
2026-06-04HANTSON LUDWIGBuy10.75K$75.13807.87K
2026-06-04Reikes Peter NOther0——
2026-06-04HANTSON LUDWIGOther0——
2026-06-01BERTHELSEN SPENCER RBuy8.00K$24.42195.36K
2026-06-01BERTHELSEN SPENCER RSell8.00K$75.67605.36K
2026-06-01BERTHELSEN SPENCER RSell8.00K$24.42195.36K
2026-05-14Monia Brett PBuy3.22K$32.60104.97K
2026-05-14Monia Brett PSell3.22K$78.68253.35K
2026-05-14Monia Brett PSell3.22K$32.60104.97K
2026-05-13Monia Brett PBuy1.32K$32.6042.90K
2026-05-13Monia Brett PSell1.32K$78.01102.67K
2026-05-13Monia Brett PSell1.32K$32.6042.90K
2026-05-04LOSCALZO JOSEPHBuy16.00K$64.801.04M
2026-05-04LOSCALZO JOSEPHBuy12.00K$60.20722.40K
2026-05-04LOSCALZO JOSEPHBuy16.00K$42.88686.08K
2026-05-04LOSCALZO JOSEPHBuy10.32K$41.08423.99K
2026-05-04LOSCALZO JOSEPHBuy12.00K$40.05480.60K
2026-05-04LOSCALZO JOSEPHSell59.51K$74.904.46M
2026-05-04LOSCALZO JOSEPHBuy10.97K$38.06417.44K
2026-05-04LOSCALZO JOSEPHSell17.78K$75.581.34M
2026-05-04LOSCALZO JOSEPHSell10.97K$38.06417.44K
2026-05-04LOSCALZO JOSEPHSell12.00K$40.05480.60K
2026-05-04LOSCALZO JOSEPHSell10.32K$41.08423.99K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 556, holders +29 vs prior quarter. Ownership 109.65%.

HolderSharesChangeChange %Value
FMR LLC24.63M75.32K+0.31%1.95B
CAPITAL WORLD INVESTORS21.67M482.86K+2.28%1.72B
BLACKROCK, INC.10.70M262.18K+2.51%848.77M
VANGUARD PORTFOLIO MANAGEMENT LLC7.86M50.63K+0.65%623.18M
WELLINGTON MANAGEMENT GROUP LLP7.65M1.26M+19.71%606.68M
VANGUARD CAPITAL MANAGEMENT LLC7.21M93.17K+1.31%571.80M
TWO SIGMA INVESTMENTS, LP6.25M394.71K+6.74%495.75M
ROYAL BANK OF CANADA6.18M2.38M+62.62%490.21M
STATE STREET CORP4.33M339.28K+8.49%343.71M
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.3.96M-2.20M-35.71%313.94M
GEODE CAPITAL MANAGEMENT, LLC3.58M-400.31K-10.05%294.75M
PRICE T ROWE ASSOCIATES INC /MD/3.18M159.25K+5.26%252.50M
JPMORGAN CHASE & CO2.67M308.15K+13.04%216.20M
ARTISAN PARTNERS LIMITED PARTNERSHIP2.64M581.72K+28.26%209.33M
TWEEDY, BROWNE CO LLC2.28M4.69K+0.21%180.81M
DEEP TRACK CAPITAL, LP2.20M250.00K+12.82%174.44M
GOLDMAN SACHS GROUP INC2.11M410.10K+24.13%167.30M
BAKER BROS. ADVISORS LP2.05M00.00%162.36M
DEERFIELD MANAGEMENT COMPANY, L.P.1.98M00.00%156.97M
AMERICAN CENTURY COMPANIES INC1.95M283.27K+17.03%154.38M
FRANKLIN TEMPLETON INC1.62M48.35K+3.07%128.72M
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.1.61M1.61MNew127.26M
CHARLES SCHWAB INVESTMENT MANAGEMENT INC1.61M21.79K+1.38%127.26M
BARCLAYS PLC1.60M1.31M+453.05%127.11M
PICTET ASSET MANAGEMENT HOLDING SA1.60M162.00K+11.29%126.98M

Insights

Revenue by product
PeriodValue
FY2015Nusinersen: 40000000.0
FY2016Akcea Therapeutics: 0.0
FY2017Akcea Therapeutics: 0.0
FY2018Commercial: 254922000.0, Licensing and Other Royalties: 14755000.0, Product: 2237000.0, Research and Development Revenue Under Collaborative Agreements: 344752000.0, SPINRAZA Royalties: 237930000.0
FY2019Commercial: 352450000.0, Licensing and Other Royalties: 17205000.0, Product: 42253000.0, Research and Development Revenue Under Collaborative Agreements: 770149000.0, SPINRAZA Royalties: 292992000.0
FY2020Commercial: 364699000.0, Licensing and Other Royalties: 8117000.0, Product: 69999000.0, Research and Development Revenue Under Collaborative Agreements: 364565000.0, Spinraza Royalties: 286583000.0
FY2021Commercial: 342395000.0, Licensing and Other Royalties: 19119000.0, Research and Development Revenue Under Collaborative Agreements: 468061000.0, Spinraza Royalties: 267776000.0, TEGSEDI and WAYLIVRA: 55500000.0
FY2022Collaborative Agreement Revenue: 207222000.0, Commercial: 303358000.0, Eplontersen Joint Development Revenue: 76787000.0, Licensing and Other Royalties: 30993000.0, Product: 30051000.0, Research and Development Revenue: 284009000.0, Spinraza Royalties: 242314000.0
FY2023Collaborative Agreement Revenue: 352657000.0, Commercial: 308591000.0, Licensing and Other Royalties: 33299000.0, Other Commercial: 68212000.0, Product: 34913000.0, Research and Development Revenue: 479056000.0, SPINRAZA Royalties: 240379000.0
FY2024Collaborative Agreement Revenue: 332647000.0, Commercial: 293076000.0, Other: 22590000.0, Other Commercial: 56779000.0, Product: 34189000.0, Research and Development Revenue: 412062000.0, SPINRAZA Royalties: 216090000.0
FY2025Commercial Member: 435848000.0, Product: 115315000.0, Royalty: 285529000.0

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Ionis Pharmaceuticals (IONS) Stock Insights

IONS$44.90+0.94 +2.14%

$7.46B

Market Cap

-12.55

P/E

112.06

Forward P/E

49

Score

Price History